Corvus Pharmaceuticals, Inc. (CRVS) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 103 institutional investors hold a position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS).

• The percentage of Corvus Pharmaceuticals owned by institutions changed from 54.4% in June 2025 to 56.0% in September 2025, marking a slight up trend.
• Institutional share ownership changed by 3.08% QoQ, while the number of institutional owners saw an increase of 66.13% YoY.
• The latest 13F cycle for Corvus Pharmaceuticals reveals that of 103 total investors, 49 funds grew their exposure, whereas 26 reduced theirs and 28 made no changes.
• The aggregate institutional position in Corvus Pharmaceuticals now stands at 41.72Mn shares as of September 2025, after investors increased their holdings (up by 1.25Mn shares quarter on quarter which is up 11.11Mn shares year over year).
• As of September 30, 2025, ORBIMED ADVISORS LLC held Corvus Pharmaceuticals's largest shareholding position with over 7.17Mn shares, representing 9.62% of total outstanding shares.
• Among the most significant buyers of Corvus Pharmaceuticals during September 2025 were BlackRock, Inc. (472.03K), STATE STREET CORP (341.55K), GOLDMAN SACHS GROUP INC (275.46K), SPHERA FUNDS MANAGEMENT LTD. (224.62K), VANGUARD GROUP INC (191.22K).
• Leading sellers of Corvus Pharmaceuticals stock in September 2025 included Point72 Asset Management, L.P. (588.10K), MORGAN STANLEY (277.18K), ROYAL BANK OF CANADA (54.11K), TWO SIGMA ADVISERS, LP (51.10K), BARCLAYS PLC (34.37K).
• The top 10 institutional holders of Corvus Pharmaceuticals for the quarter ending September 2025 included ORBIMED ADVISORS LLC (7.17Mn), Point72 Asset Management, L.P. (6.45Mn), BlackRock, Inc. (4.71Mn), VANGUARD GROUP INC (3.47Mn), ADAMS STREET PARTNERS LLC (3.28Mn), RTW INVESTMENTS, LP (2.68Mn), Vivo Capital, LLC (2.23Mn), Foresite Capital Management VI LLC (1.73Mn), GEODE CAPITAL MANAGEMENT, LLC (1.46Mn), PERCEPTIVE ADVISORS LLC (1.44Mn).